Showing 5141-5150 of 21466 results for "".
- Platelet-Rich Plasma May Function as a Bioregulatory System in Soft-Tissue Remodelinghttps://reachmd.com/news/platelet-rich-plasma-may-function-as-a-bioregulatory-system-in-soft-tissue-remodeling/2487555/A newly published review in Aesthetic Plastic Surgery examines the evolving understanding of platelet-rich plasma (PRP), suggesting that its role in soft-tissue repair extends beyond conventional growth-factor delivery and may involve broader regulation of the tissue microenvironment.
- Mental Health Burden in Long-Term Survivors of Childhood and Young Adult Cancerhttps://reachmd.com/news/mental-health-survivors-childhood-young-adult-cancer/2487550/Key Takeaways First mental health events were more common in five-year survivors of cancer diagnosed before age 40 than in matched comparators without a cancer history. Higher incidence in survivors was observed across follow-up intervals, with hazard
- Conditional Medicaid Expansion and Mental Healthhttps://reachmd.com/news/conditional-medicaid-expansion-and-mental-health-in-georgia/2487534/Key Takeaways Compared with neighboring nonexpansion states, low-income adults in Georgia reported more days in the past month when mental health was not good after Pathways began. A second primary outcome also moved in the same direction, with more re
- Tiger Aesthetics Launches BioBody and BioDerma Divisions to Expand Aesthetics Market Reachhttps://reachmd.com/news/tiger-aesthetics-launches-biobody-and-bioderma-divisions-to-expand-aesthetics-market-reach/2487530/Tiger Aesthetics Medical™ has announced a new commercial structure centered on 2 dedicated divisions—BioBody™ and BioDerma™—as the company seeks to accelerate growth and expand market penetration across medical aesthetics. According to the company, the reorganization is supported by increa
- RRS® HA LONG LASTING Earns Top Skin Revitalization Honor at AMWC 2026https://reachmd.com/news/rrs-ha-long-lasting-earns-top-skin-revitalization-honor-at-amwc-2026/2487529/Skin Tech Pharma Group announced that RRS® HA LONG LASTING has been awarded Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, a recognition presented during the Aesthetic & Anti-Aging Medicine World Congress (AMWC). The award recognizes RRS
- Exa-Cel in Children With Transfusion-Dependent Beta Thalassemia or Sickle Cell Diseasehttps://reachmd.com/news/exa-cel-in-children-with-transfusion-dependent-beta-thalassemia-or-sickle-cell-disease/2487526/Key Takeaways All evaluable children in the beta thalassemia cohort became transfusion independent, and all evaluable children in the sickle cell disease cohort had no severe vaso-occlusive crises. The findings came from two ongoing phase 3, open-label
- SNAP Trial Reports Cefazolin Safety And Effectiveness In MSSA Bacteremiahttps://reachmd.com/news/snap-trial-reports-cefazolin-safety-and-effectiveness-in-mssa-bacteremia/2487527/Key Takeaways Cefazolin was reported to perform at least as well as cloxacillin or flucloxacillin for MSSA bacteremia. Cefazolin was associated with fewer side effects and fewer cases of acute kidney injury in the reported comparison. The find
- Cellese Appoints Christopher Hausman as CEO to Lead Next Phase of Growth in Regenerative Aestheticshttps://reachmd.com/news/cellese-appoints-christopher-hausman-as-ceo-to-lead-next-phase-of-growth-in-regenerative-aesthetics/2487520/Cellese Inc., the regenerative aesthetics company behind the AnteAGE® skincare brand, has appointed Christopher Hausman as Chief Executive Officer, the company announced. Hausman joins Irvine, California-based Cellese with more than 3 decades of experience in the aesthetics, skincare, dent
- Talquetamab and Daratumumab in Relapsed or Refractory Myelomahttps://reachmd.com/news/talquetamab-daratumumab-relapsed-refractory-myeloma/2487509/Key Takeaways Both talquetamab-containing regimens were associated with longer progression-free survival than the daratumumab-based control at interim analysis. Overall response, complete response or better, and MRD-negative complete response were high
- One-Minute Oscillometry vs Continuous Arterial Pressure Monitoringhttps://reachmd.com/news/oscillometry-continuous-arterial-pressure-monitoring/2487514/Key Takeaways One-minute oscillometric monitoring met the prespecified noninferiority criterion for the primary induction hypotension endpoint. Vasopressors, particularly phenylephrine, were used less often in the oscillometry group than in the continu